Blood-clotting illness PVT 30x more prevalent in Moderna, Pfizer Covid-19 recipients than AstraZeneca – Oxford researchers

A potentially fatal blood-clotting disease is 30 times more common among people who have received the Covid-19 vaccines produced by Moderna and Pfizer than those given the troubled AstraZeneca jab, researchers have found.

A team of scientists from the University of Oxford has found that after vaccination, Vaxzevria (formerly AstraZeneca Covid-19 vaccine) recipients were less likely to suffer portal vein thrombosis (PVT) – blood clots in the artery from the intestines to the liver.

READ  HMM: At Least 9,245 Americans Tested Positive for COVID-19 After Vaccination; 132 Dead.

For recipients of the viral vector Vaxzevria vaccine, the incidence rate for splanchnic thrombosis – clotting in the portal and other abdominal veins – is 1.6 per million people, according to data from the EU drugs regulator the European Medicines Agency (EMA). By contrast, some 44.9 cases of PVT per million people were seen among those who had been injected with the mRNA vaccines made by Moderna and Pfizer, the Oxford research, published on Thursday, said.

READ  Covid Insanity - Mobile Isolation Tent (short video)

 

www.rt.com/news/521313-pvt-bloodclot-mrna-covid-vaccines/

1,055 views

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.